Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis

An enhanced understanding of the molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) has opened the door to clinical trials evaluating novel agents with subtype-specific activity. It is an emerging question whether core needle biopsies (CNB) can adequately meet the increasing tissue req...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Sanjal H., Mwangi, Raphael, Ng, Wern Lynn, King, Rebecca L., Maurer, Matthew J., Cerhan, James R., Feldman, Andrew L., Farooq, Umar, Mou, Eric, Habermann, Thomas M., Thompson, Carrie A., Wang, Yucai, Witzig, Thomas E., Nowakowski, Grzegorz S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791316/
https://www.ncbi.nlm.nih.gov/pubmed/36170803
http://dx.doi.org/10.1182/bloodadvances.2022007569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791316/
https://www.ncbi.nlm.nih.gov/pubmed/36170803
http://dx.doi.org/10.1182/bloodadvances.2022007569

Ejemplares similares